1st Jul 2016 16:25
GlaxoSmithKline plc
Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons
In accordance with Disclosure and Transparency Rule 3.1.4R(1)(a), I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc (the 'Company').
On 30 June 2016, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £15.59 per Ordinary Share, and notional ADSs at a price of $42.37 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2016 to 30 June 2016:
Non Executive Director | Ordinary Shares | No. of ADSs | |
Sir Philip Hampton | 2,806.286 |
| |
Professor Sir Roy Anderson | 581.302 |
| |
Vindi Banga | 2,140.172 |
| |
Stacey Cartwright | 461.033 |
| |
Lynn Elsenhans | 845.582 |
| |
Judy Lewent | 436.213 |
| |
Urs Rohner | 541.212 |
| |
Jesse Goodman was appointed to the Board with effect from 1 January 2016. In accordance with the share allocation arrangements for Non-Executive Directors, 25% of Jesse Goodman's fees will be retained and will be reinvested in the Company's ADSs at a future date, to be mutually agreed.
The Company and the Non-Executive Directors were advised of these allocations on 1 July 2016.
V A Whyte
Company Secretary
1 July 2016
Related Shares:
Glaxosmithkline